Navigation Links
Is Chronic Pain Keeping You Awake? Help Is On the Way
Date:10/22/2013

WALTHAM, Mass., Oct. 22, 2013 /PRNewswire/ -- According to some studies, more than 100 million people in North America live with—or perhaps more accurately, don't find it easy to live with—days and nights filled with chronic pain. They know that persistent pain does more than make one achy and perhaps a bit cranky. Chronic pain has been associated with a significant increase in the rate of depression and anxiety. Most of those who have to endure chronic pain may also have problems with attention, memory, high blood pressure and related heart problems, along with sleep issues. Common causes of pain include degenerative spine disease, lower back pain, rheumatoid arthritis, osteoarthritis, fibromyalgia, HIV, migraine, neuropathy and complications of shingles.

This population includes approximately five million people with Type 2 diabetes who experience chronic pain, a condition called painful diabetic neuropathy (PDN). It is estimated that about half of them suffer pain that keeps them from getting to sleep, or when they do, staying asleep.   

Neuropathy in Type 2 diabetes can frustrate both patients and their doctors and other health providers. Although there is a range of treatments, including pharmaceutical painkillers, antidepressants, anticonvulsants, steroid and cortisone injections, analgesic patches, vitamin B shots and hot/cold packs, relief is often elusive or sporadic. People with chronic pain may need a deep, restorative night's rest to fully function.  

The good news is that there has been a major advance for PDN: the SENSUS Pain Management System. SENSUS has been developed by NeuroMetrix Inc., a medical device company in Waltham, Massachusetts. SENSUS offers transcutaneous electrical nerve stimulation and is the first device of its kind to receive 510(k) clearance from the U.S. Food and Drug Administratio
'/>"/>

SOURCE NeuroMetrix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Chronic Use of Prescription Painkillers Continues Following Bariatric Surgery
2. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
3. Aptel Research Launches Unique Patient-centric Syndicated Report Series That Analyze the Patient Journey for Chronic Diseases in Specialty Markets
4. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
5. Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
7. SanBio Announces The Completion Of Enrollment Of Its Clinical Trial Of Cell Therapy For Chronic Stroke Deficits
8. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
9. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
10. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... September 15 NicOx S.A. (Euronext,Paris: COX) today ... study for naproxcinod in 1020 patients with osteoarthritis ... naproxcinod (750 mg and 375 mg bid) met,the ... study,also comfortably met the main secondary endpoint, demonstrating ...
... ... Osteoarthritis, WALTHAM, ... announced today that Kenneth Kornman, Ph.D.,the company,s Chief Scientific Officer, ... (OA) at the 2008 World Congress,on Osteoarthritis, sponsored by the ...
Cached Medicine Technology:NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 2NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 3NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 4NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect 5Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 2Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 3Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis 4
(Date:8/30/2014)... The establishment and creation of ... one of the main strategies of the Church ... impact around the world. , Architecturally stellar buildings ... executives and trainers deliver L. Ron Hubbard's spiritual ... statistics demonstrate that significant reduction in crime, major ...
(Date:8/30/2014)... Seniors Guide, the comprehensive guide to all things senior, ... Disease, Dementia, and Memory Loss . , Country singer Glen ... with the Alzheimer’s, inspired Seniors Guide writers to review the ... movie, out on October 14, 2014, shows a glimpse of ... disease – which inspires a final tour from the musician ...
(Date:8/30/2014)... By Randy Dotinga ... -- About one in five patients operated on for broken ... after surgery, a new study finds. Less-educated patients ... times more likely to be "doctor shoppers," said study lead ... Lexington, Ky. Overall, he said, the study suggests that doctors ...
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 2Health News:'Doctor-Shopping' for Painkillers Common After Broken-Bone Surgery, Study Finds 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... ARLINGTON, Va., Nov. 16 Acknowledging that their results ... in the International Journal of Andrology nevertheless attempt to link ... to maternal exposure to phthalates. The researchers, led by ... previous, and much publicized, study of phthalate exposure to evaluate ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 15 ... Company will hold a teleconference and webcast at 8:00 a.m. Eastern ... Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of ... Conference Call and Webcast Information , To participate ...
... 15 The World Champion New York Yankees ... at New York Blood Center,s (NYBC) Biennial Chairman,s Dinner this ... The event is chaired by William J. Mullaney, MetLife ... the opportunity to honor these two outstanding supporting organizations as ...
... ... its intention to begin the drug registration process in Brazil and Colombia for its ... United States for the treatment of moderate to severe (Stage 2) chronic pain. ... Plantation, FL (Vocus) ...
... , ... from the RecordAF,registry (REgistry on Cardiac rhythm disORDers assessing ... Sessions of the,American Heart Association, show that in recently ... rhythm-control strategy,provides better short term control of the arrhythmia ...
... when new lead is needed in heart devices, ... -- Replacing or adding wiring increases the risk ... replace a pacemaker or other heart rhythm-stabilizing device, ... complication rates among patients enrolled in the REPLACE ...
Cached Medicine News:Health News:Swan Study Authors Note Results 'Not Straightforward' 2Health News:Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer 2Health News:World Champion New York Yankees, BNY Mellon to be Honored as New York Blood Center 'Champions of Life' 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 2Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 3Health News:Nutra Pharma Announces Plans to Begin Drug Registration Process in South America for its Over-the-Counter Pain Reliever 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 2Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 3Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 4Health News:First Global Atrial Fibrillation Registry, RecordAF, Shows Rhythm-Control Strategy With Current Therapies Achieves Improved Disease Control but not Clinical Outcomes 5
... to having been designed exclusively for vascular treatments, ... the Smartepil range which ensures fast amortisation of ... systems, it can be fitted with a polarised ... the target to be treated as well as ...
... SmartLite Derm is a KTP laser, ... of 532 nm (frequency doubled Nd:YAG) for ... by the comfortable color LCD Touch-screen. ... available are 0.3, 0.5, 0.7 and 1.0 ...
... a new and powerful instrument for ... system (MEL @308 nm - UVB) ... vitiligo. Designed to treat recalcitrant plaques, ... exposure of extensive lesions without irradiating ...
... a CO2 laser system with CW intensities ... dealing with all therapeutic application in modern ... medium-to-high intensities in super-pulsed mode, designed for ... It is also capable of supplying soft ...
Medicine Products: